To describe the clinical characteristics and evolution of our series of medication-related osteonecrosis of the jaws (MRONJ) associated with denosumab in osteoporotic patients.MATERIAL AND METHODS
We present 10 new cases of MRONJ in patients receiving denosumab for osteoporosis. We describe the mean doses of denosumab, previous bisphosphonate intake, and the clinical characteristics associated with the osteonecrosis, such as local contributing factors, symptoms, and evolution after treatment.RESULTS
The mean number of denosumab doses was 3.4 ± 2.2. In 90% of patients, there wasa priorhistory of oral bisphosphonate intake, with a mean duration of 46.78 ± 25.11 months. The most common local factor was dental extraction (6 cases; 60%), and most cases had necrotic bone exposure (9/10, 90%). Sclerosis of the bone was the most common radiographic finding. Stage 1 was the most common ONM stage, found in 80%. ‘Cure’ after conservative treatments was obtained in 71.4%.CONCLUSIONS
Most of our cases were in the early stages of MRONJ, and the success rate after conservative treatment was high.